Abstract：
BACKGROUND:Succinylated human serum albumin (Suc-HAS) is a negatively charged neo-glycoprotein that binds to the positively charged V3-loop of HIV-1 gp120, acting as HIV-1-fusion inhibitor in vitro (IC50: 0.5-5.0 microg/ml). Suc-HSA was safe in rats and monkeys, and showed antiretroviral effect in a human-to-mouse model. We evaluated safety and pharmacokinetics of single and multiple doses of Suc-HSA in HIV-1-infected individuals. METHODS:First, six untreated, chronically HIV-1-infected patients were randomized to a single dose of 1 or 10 mg/kg Suc-HSA intravenously. Second, five consecutive daily doses (10 mg/kg, based on the results of the single dose study) were given to four patients. Safety laboratory assessments, Suc-HSA plasma levels, plasma HIV-1 RNA (pVL), and CD4+ T-cell counts were determined. RESULTS:Increase of liver transaminases (grade 1/2) occurred in one of six patients in the single-dose phase and in three of four patients in the multiple-dosing phase. Suc-HSA plasma levels were undetectable 4 h after a single dose of 1 mg/kg. After a dose of 10 mg/kg, plasma levels were more sustained, but declined under the target plasma concentration (10 microg/ml) 12-24 h post-dosing. After multiple dosing, plasma levels reached peak values 2h post-dosing as predicted by our kinetic model. However, trough levels were below the target concentrations. There was no change in pVL or CD4+ T-cell count in either the single- or multiple-dosing phase. CONCLUSIONS:At the chosen dosing regimens, adequate antiviral plasma levels were not maintained, probably because the hepatic clearance was more rapid than expected. This may partially explain the lack of effect on pVL and CD4+ T-cell count. The observed liver transaminase increases prohibit further dose escalation.
journal_name
Antivir Therjournal_title
Antiviral therapyauthors
Vermeulen JN,Meijer DK,Over J,Lange J,Proost JH,Bakker HI,Beljaars L,Wit FW,Prins JMsubject
Has Abstractpub_date
2007-01-01 00:00:00pages
273-8issue
2eissn
1359-6535issn
2040-2058journal_volume
12pub_type
杂志文章,随机对照试验abstract：BACKGROUND:We sought to determine whether markers of systemic inflammation are associated with the presence of moderate/severe obstructive sleep apnea (OSA) and whether this association differs based on HIV and HIV treatment status. METHODS:HIV-uninfected men (HIV-; n=60), HIV-infected men receiving HAART (HIV+/HAART;...
journal_title：Antiviral therapy
pub_type： 杂志文章,多中心研究
doi：10.3851/IMP2745
更新日期：2014-01-01 00:00:00
abstract：:Clinical research has indicated that the use of nucleoside reverse transcriptase inhibitor (NRTI) and HIV protease inhibitor (PI) therapy is associated with a risk of long-term toxicity syndromes, and that the aetiopathogenesis of these adverse effects is independent of the antiretroviral effects of these drugs. In re...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：
更新日期：2001-09-01 00:00:00
abstract：BACKGROUND:Serum HBV RNA is detectable during nucleoside/nucleotide analogue therapy as a result of unaffected RNA replicative intermediates or interrupted reverse transcription. We studied the predictive value of serum HBV RNA for initial virological response during nucleoside analogue therapy. METHODS:Serum HBV RNA ...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2777
更新日期：2015-01-01 00:00:00
abstract：:Transmission of drug-resistant variants is influenced by several factors, including the prevalence of drug resistance in the population of HIV-1-infected patients, HIV-1 RNA levels and transmission by recently infected patients. In order to evaluate the impact of these factors on the transmission of drug-resistant var...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2004-06-01 00:00:00
abstract：:HIV escape in the central nervous system (CNS) despite undetectable viral load in the plasma has been observed and may contribute to HIV-associated neurocognitive disorders. Favouring the use of HIV drugs with a good penetration into the CNS has been advocated, leading to the establishment of the CNS penetration-effec...
journal_title：Antiviral therapy
pub_type： 评论,杂志文章
doi：10.3851/IMP2561
更新日期：2013-01-01 00:00:00
abstract：BACKGROUND:Current stopping rules during pegylated interferon (peg-IFN)/ribavirin (RBV) treatment rely on week 12 HCV RNA response, but earlier identification of non-responders offers clinical and economic advantages. AIMS AND METHODS:To evaluate, among 129 HCV-genotype-1-infected, treatment-naive patients receiving p...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2007-01-01 00:00:00
abstract：BACKGROUND:The objective of this study was to compare indinavir peak plasma (Cmax) values after administration of indinavir/ritonavir 800/100 mg on an empty stomach or with food. High indinavir Cmax values have been associated with indinavir-related nephrotoxicity. METHODS:This was an open-label, randomized, two-treat...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章,随机对照试验
doi：
更新日期：2003-08-01 00:00:00
abstract：BACKGROUND:This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment. METHODS:A total of 243 patients from Cameroon receiving d4T or zidovudine (AZT) in combination with lamivudine and efavirenz or nevirapine for >6 months were clinically assesse...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP1664
更新日期：2010-01-01 00:00:00
abstract：OBJECTIVE:To assess the impact of nucleoside analogue reverse transcriptase inhibitor (NRTI) combination therapy on muscle and liver lactate metabolism in HIV-infected patients. METHODS:This cross-sectional study involved HIV-infected patients who were either antiretroviral-naive (Group 1) or were receiving either a s...
journal_title：Antiviral therapy
pub_type： 杂志文章,多中心研究
doi：
更新日期：2005-01-01 00:00:00
abstract：BACKGROUND:In China, the optimal management of individuals living with chronic HBV infection remains an unmet need. The EVOLVE was a 5-year prospective, longitudinal, observational study that compared the clinical outcomes in treatment-naïve CHB patients receiving entecavir (ETV) or lamivudine (LAM)-based therapies. M...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3372
更新日期：2020-10-22 00:00:00
abstract：BACKGROUND:Poor adherence to antiretroviral therapy contributes to pharmacokinetic variability and is the major determinant of virological failure. However, measuring treatment adherence is difficult, especially in children. We investigated the relationship between plasma lopinavir concentrations, pretreatment characte...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2749
更新日期：2014-01-01 00:00:00
abstract：BACKGROUND:The potential use of variola virus as a biological weapon has renewed efforts in the development of antiviral agents against orthopoxviruses. ST-246 [4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-di oxo-4,6-ethenocycloprop [f]isoindol-2(1 H)-yl)-benzamide] is an anti-orthopoxvirus compound active ag...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2007-01-01 00:00:00
abstract：BACKGROUND:Nucleoside (or nucleotide) reverse transcriptase inhibitors (NRTIs) cause side effects in some patients, prompting the use of either partly or fully NRTI-sparing regimens. METHODS:We used data from the Swiss HIV Cohort Study to estimate the effectiveness of two new dolutegravir dual regimens relative to the...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3310
更新日期：2019-01-01 00:00:00
abstract：:All illnesses and, by association, all provision of health care in any setting have a cost, whether it is the direct cost to the consumer, to the provider (for example, a national health service) or the indirect cost to an employer or to society in lost production. Disease also has hidden or intangible costs of pain, ...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：
更新日期：1999-01-01 00:00:00
abstract：:Boceprevir and telaprevir are peptidomimetic serine protease inhibitors that have been recently approved for the treatment of HCV chronic infection. The addition of these drugs to the prior standard of care, pegylated interferon and ribavirin, improves sustained virological response rates for treatment-naive and treat...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：10.3851/IMP2424
更新日期：2012-01-01 00:00:00
abstract：BACKGROUND:The tendency for haemorrhagic stroke in patients with chronic HCV infection has emerged recently but the finding may be confounded by comorbidities. Proving the causality between HCV infection and haemorrhagic stroke is mandatory. Our study was designed to investigate the incidence of intracranial haemorrhag...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3172
更新日期：2018-01-01 00:00:00
abstract：BACKGROUND/AIMS:The role of antibody in hepatitis C virus (HCV) infection remains unclear although many reports attest to its role in viral clearance. Here we describe epitopes that are recognized by antibody present in the serum of infected patients and show that such epitopes can induce neutralizing antibodies. METH...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2006-01-01 00:00:00
abstract：BACKGROUND:Lamivudine is widely used in patients with chronic hepatitis B virus (HBV) infection. In cirrhotic patients, long-term lamivudine therapy significantly reduced the risk of hepatocellular carcinoma (HCC). However, in a small but substantial portion of patients, HCC still developed despite lamivudine therapy. ...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2009-01-01 00:00:00
abstract：INTRODUCTION:Patients with hepatitis C recurrence after liver transplantation represent a clinical challenge. Antiviral treatment in transplant patients has usually poor tolerability and limited efficacy, with a mean sustained virological response (SVR) of 30%. Our pilot study was aimed at evaluating whether 8-week rib...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP1834
更新日期：2011-01-01 00:00:00
abstract：BACKGROUND:In haematopoietic stem cell transplant (HSCT) recipients, cytomegalovirus (CMV) infection contributes significantly to morbidity and mortality in both the early and late post-transplant period. Ganciclovir (GCV) is the treatment of choice for CMV, but requires intravenous administration, a fact that complica...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP1858
更新日期：2011-01-01 00:00:00
abstract：BACKGROUND:Voxilaprevir (VOX; GS-9857) is a pangenotypic HCV NS3/4A protease inhibitor (PI) with potent antiviral activity against HCV genotypes (GTs) 1-6 and improved coverage of GT1 NS3 resistance-associated substitutions (RAS) associated with other HCV PIs. In a 3-day Phase Ib monotherapy study in patients infected ...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章,多中心研究,随机对照试验
doi：10.3851/IMP3202
更新日期：2018-01-01 00:00:00
abstract：BACKGROUND:Rilpivirine-based regimens are now preferred or alternative first-line regimens according to many HIV treatment guidelines. Recently, a surveillance study conducted in Argentina determined that prevalence of pretreatment resistance to first-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) ...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3147
更新日期：2017-01-01 00:00:00
abstract：BACKGROUND:Across sub-Saharan Africa, men who have sex with men (MSM) and transgender women (TGW) have disproportionately poor HIV treatment outcomes. Stigma and criminalization create barriers to health-care engagement and adherence to antiretroviral therapy (ART), potentially promoting the development of HIV drug res...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3342
更新日期：2019-01-01 00:00:00
abstract：OBJECTIVE:In patients with a chronic asymptomatic HIV-1 infection and >200 CD4+ T-cells/microl, the optimal timing of highly active antiretroviral therapy (HAART) initiation is unclear. It involves a trade-off between a potentially reduced risk of mortality, when started earlier in the course of infection, and an earli...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2006-01-01 00:00:00
abstract：:Weighted genotypic resistance scores represent a step towards excellence in the interpretation of HIV type-1 (HIV-1) resistance to antiretroviral drugs. They can predict phenotypic resistance and clinical response better than any other unweighted score. With the addition of mutations associated with an increased respo...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP1671
更新日期：2010-01-01 00:00:00
abstract：BACKGROUND:Two distinct inhibitors of the HCV protease have been approved for the treatment of patients infected with HCV genotype-1. These drugs are highly efficient in suppressing HCV replication; however, their use is limited by the emergence of viral mutants resistant to them after a very short time of treatment. B...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2326
更新日期：2013-01-01 00:00:00
abstract：BACKGROUND:Dyslipidaemia and lipodystrophy have been described in treated HIV patients and in a small percentage of untreated HIV patients. Lipodystrophy in these patients has been shown to be associated with a lower expression of low density lipoprotein (LDL) receptors. METHODS:We have investigated the effect of anti...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2005-01-01 00:00:00
abstract：:The aim of this study (the RESCUE trial) was to verify the effect of a shift from a lamivudine-containing to a didanosine-containing regimen on viral replication in HIV-1-infected subjects who had experienced prior treatment failure. Sixteen patients (didanosine-experienced in 14/16 cases) were consecutively enrolled:...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2001-03-01 00:00:00
abstract：:Compounds that can block the CXCR4 chemokine receptor are a promising new class of antiretroviral agents. In these experiments we studied the effect of a modified form of the native stromal cell-derived factor-1 (SDF-1), Met-SDF-1beta. The in vitro susceptibility of two different CXCR4-tropic HIV-1 strains was determi...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2000-09-01 00:00:00
abstract：BACKGROUND:The World Health Organization recommends HBV-HIV-coinfected individuals start antiretroviral therapy containing tenofovir. Here we describe first-line tenofovir use and treatment outcomes in coinfected patients in Asia. METHODS:HBV surface antigen positive patients enrolled in the TREAT Asia HIV Observation...
journal_title：Antiviral therapy
pub_type： 杂志文章,多中心研究
doi：10.3851/IMP2972
更新日期：2016-01-01 00:00:00
